1stOncology™: Cancer Intelligence Service – Page 15639 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Unum Therapeutics to Host Investor Event on its Efforts to Realize the Promise of T Cell Therapies in Solid Tumors

On November 12, 2018 Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, reported that the Company will host an investor event to discuss its efforts in solid tumors on Monday November 19, 2018, from 8:30 a.m. to 10:00 a.m. ET in New York City (Press release, Unum Therapeutics, NOV 12, 2018, View Sourcenews-releases/news-release-details/unum-therapeutics-host-investor-event-its-efforts-realize" target="_blank" title="View Sourcenews-releases/news-release-details/unum-therapeutics-host-investor-event-its-efforts-realize" rel="nofollow">View Source [SID1234531331]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

The event will feature guest speaker Charles S. Fuchs, MD, MPH, Director of the Yale Cancer Center, who will discuss the challenges and opportunities in HER2 malignancies. In addition, the Company will discuss the unmet need, clinical validation of ACTR707 and design of the ATTCK-34-01 Phase I trial using ACTR707 in combination with trastuzumab to target HER2-positive advanced cancers. The Company also will provide more details on the new BOXR platform to support its growing efforts in solid tumors.

To join the live webcast, please visit the investor relations section of the Unum Therapeutics website at View Source at least 10 minutes before the event begins.

Complix to Present its Cell Penetrating Alphabodies Acting on Important Intracellular Targets at PEGS Europe 2018

On November 12, 2018 Complix, a biopharmaceutical company developing a pipeline of transformative Cell Penetrating Alphabodies (CPABs) reported that its Chief Scientific Officer, Dr Yvonne McGrath, will be presenting recent developments on CPABs against intracellular targets at the 10th Annual PEGS Europe Meeting (Protein and Antibody Engineering Summit) in Lisbon Portugal, November 12-16 (Press release, Complix, NOV 12, 2018, View Source [SID1234531276]).

In her presentation Dr McGrath will provide an update on Complix’ recent progress with respect to CAPBs acting on important intracellular cancer targets. In particular Dr McGrath will be showing results obtained with CPABs targeting the enhanceosome of the Wnt pathway, a key pathway involved in development of cancer and other major diseases.

Details of the talk are as follows:

Title: "Cell Penetrating Alphabodies to Access Undruggable Intracellular Targets"
Session: "Engineering Antibodies"
Time: November 14 at 09:05 CET

Agilent Technologies to Present at Evercore ISI HealthCONx

On November 12, 2018 Agilent Technologies Inc. (NYSE: A) reported the following webcast for the investment community (Press release, Agilent, NOV 12, 2018, http://www.agilent.com/about/newsroom/presrel/2018/12nov-gp18060.html [SID1234531275]):

Evercore ISI HealthCONx
Boston Harbor Hotel, Boston, Massachusetts
Tuesday, November 27, 2018 at 2:00 p.m. ET
Mike McMullen, Agilent president and chief executive offic

Johnson & Johnson to Participate in the Citi’s 2018 Global Healthcare Conference

On November 12, 2018 Johnson & Johnson (NYSE: JNJ) reported that it will participate in the Citi’s 2018 Global Healthcare Conference on Wednesday, December 5th, at the Lotte New York Palace Hotel in New York City (Press release, Johnson & Johnson, NOV 12, 2018, View Source [SID1234531274]). Joseph J. Wolk, Executive Vice President and Chief Financial Officer will represent the Company in a session scheduled at 10:15 a.m. (Eastern).

This webcast will be available to investors and other interested parties by accessing the Johnson & Johnson website at www.investor.jnj.com.

A webcast replay will be available approximately two hours after the live webcast.

Prometic to report its third quarter 2018 financial results and hold conference call / webcast

On November 12, 2018 Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) ("Prometic") reported that it will report its financial results for the third quarter ended September 30, 2018 on Wednesday November 14, 2018 after market close (Press release, ProMetic Life Sciences, NOV 12, 2018, https://resources.prometic.com/latest-content/prometic-to-report-its-third-quarter-2018-financial-results-and-hold-conference-call-webcast [SID1234531241]).

Prometic will host a conference call at 11:00am (ET) on Thursday November 15, 2018. The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. An audio replay of the call will be available as of Thursday November 15, 2018 at 2:00pm (ET). The numbers to access the audio replay are 416-849-0833 and 1-855-859-2056 using the following password (1190238).